"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Descriptor ID |
D007167
|
MeSH Number(s) |
E02.095.465.425
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 1 | 1 | 2 |
1996 | 1 | 0 | 1 |
1998 | 0 | 3 | 3 |
1999 | 2 | 1 | 3 |
2000 | 3 | 2 | 5 |
2001 | 2 | 5 | 7 |
2002 | 2 | 3 | 5 |
2003 | 2 | 4 | 6 |
2004 | 5 | 8 | 13 |
2005 | 3 | 2 | 5 |
2006 | 4 | 2 | 6 |
2007 | 4 | 1 | 5 |
2008 | 7 | 6 | 13 |
2009 | 4 | 2 | 6 |
2010 | 7 | 5 | 12 |
2011 | 5 | 5 | 10 |
2012 | 8 | 7 | 15 |
2013 | 8 | 9 | 17 |
2014 | 8 | 9 | 17 |
2015 | 9 | 16 | 25 |
2016 | 20 | 2 | 22 |
2017 | 22 | 3 | 25 |
2018 | 31 | 14 | 45 |
2019 | 29 | 16 | 45 |
2020 | 19 | 25 | 44 |
2021 | 22 | 20 | 42 |
2022 | 2 | 30 | 32 |
2023 | 2 | 29 | 31 |
2024 | 11 | 13 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Cells. 2024 Jul 30; 13(15).
-
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies. J Immunother Cancer. 2024 Jul 29; 12(7).
-
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nat Commun. 2024 Jun 28; 15(1):5487.
-
Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia. 2024 Aug; 65(8):e148-e155.
-
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e433330.
-
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC. J Thorac Oncol. 2024 Jun; 19(6):877-882.
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
-
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
-
Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024 May 08; 8(3).
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.